Monopar Therapeutics Inc. (MNPR)
MNPR Stock Price Chart
Explore Monopar Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze MNPR price movements and trends.
MNPR Company Profile
Discover essential business fundamentals and corporate details for Monopar Therapeutics Inc. (MNPR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Dec 2019
Employees
22.00
Website
https://www.monopartx.comCEO
Chandler D. Robinson
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
MNPR Financial Timeline
Browse a chronological timeline of Monopar Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.67.
Earnings released on 14 May 2026
EPS came in at -$0.46 surpassing the estimated -$1.06 by +56.60%.
Earnings released on 27 Mar 2026
EPS came in at -$0.61 falling short of the estimated -$0.51 by -19.08%.
Earnings released on 13 Nov 2025
EPS came in at -$0.48 falling short of the estimated -$0.46 by -4.35%.
Earnings released on 12 Aug 2025
EPS came in at -$0.35 surpassing the estimated -$0.47 by +25.53%.
Earnings released on 13 May 2025
EPS came in at -$0.38 surpassing the estimated -$0.65 by +41.54%.
Earnings released on 31 Mar 2025
EPS came in at -$2.23 falling short of the estimated -$0.36 by -519.44%.
Earnings released on 8 Nov 2024
EPS came in at -$0.37 surpassing the estimated -$0.46 by +19.57%.
Stock split effective on 13 Aug 2024
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Aug 2024
EPS came in at -$0.50 falling short of the estimated -$0.45 by -11.11%.
Earnings released on 9 May 2024
EPS came in at -$0.50 surpassing the estimated -$0.85 by +41.18%.
Earnings released on 28 Mar 2024
EPS came in at -$0.60 surpassing the estimated -$0.85 by +29.41%.
Earnings released on 9 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$0.95 by +26.32%.
Earnings released on 10 Aug 2023
EPS came in at -$0.80 surpassing the estimated -$0.95 by +15.79%.
Earnings released on 11 May 2023
EPS came in at -$0.95 surpassing the estimated -$1.00 by +5.00%.
Earnings released on 23 Mar 2023
EPS came in at -$1.10 falling short of the estimated -$1.05 by -4.76%.
Earnings released on 10 Nov 2022
EPS came in at -$0.95 surpassing the estimated -$1.15 by +17.39%.
Earnings released on 11 Aug 2022
EPS came in at -$1.10 falling short of the estimated -$1.05 by -4.76%.
Earnings released on 12 May 2022
EPS came in at -$0.95 surpassing the estimated -$1.20 by +20.83%.
Earnings released on 24 Mar 2022
EPS came in at -$1.05 falling short of the estimated -$0.90 by -16.67%.
Earnings released on 12 Nov 2021
EPS came in at -$1.00 surpassing the estimated -$1.10 by +9.09%.
Earnings released on 12 Aug 2021
EPS came in at -$0.85 surpassing the estimated -$1.05 by +19.05%.
MNPR Stock Performance
Access detailed MNPR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
